Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders treatment solutions, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, before market open.
The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results. Investors can access the live webcast through the provided link, and telephone participants are encouraged to register and join 10 minutes before the event starts.
Neuronetics (NASDAQ: STIM), un'azienda di tecnologia medica specializzata in soluzioni per il trattamento dei disturbi neuro-sanitari, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per martedì 5 agosto 2025, prima dell'apertura dei mercati.
La società terrà una conference call alle 8:30 del mattino, ora Eastern lo stesso giorno per discutere i risultati. Gli investitori potranno accedere alla diretta web tramite il link fornito, e i partecipanti telefonici sono invitati a registrarsi e collegarsi 10 minuti prima dell'inizio dell'evento.
Neuronetics (NASDAQ: STIM), una empresa de tecnología médica especializada en soluciones para el tratamiento de trastornos neuro-salud, ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el martes 5 de agosto de 2025, antes de la apertura del mercado.
La compañía realizará una llamada en conferencia a las 8:30 a.m., hora del Este el mismo día para discutir los resultados. Los inversores pueden acceder a la transmisión en vivo a través del enlace proporcionado, y se recomienda a los participantes telefónicos registrarse y unirse 10 minutos antes de que comience el evento.
Neuronetics (NASDAQ: STIM)는 신경 건강 장애 치료 솔루션을 전문으로 하는 의료 기술 회사로, 2025년 2분기 재무 실적 발표를 2025년 8월 5일 화요일 시장 개장 전으로 예정했습니다.
회사는 같은 날 동부 표준시 오전 8시 30분에 실적에 대해 논의하는 컨퍼런스 콜을 진행할 예정입니다. 투자자들은 제공된 링크를 통해 생중계 웹캐스트에 접속할 수 있으며, 전화 참가자는 행사 시작 10분 전에 등록하고 참여할 것을 권장합니다.
Neuronetics (NASDAQ : STIM), une entreprise de technologie médicale spécialisée dans les solutions de traitement des troubles neuro-santé, a programmé l'annonce des résultats financiers du deuxième trimestre 2025 pour le mardi 5 août 2025, avant l'ouverture des marchés.
L'entreprise organisera une conférence téléphonique à 8h30, heure de l'Est le même jour pour discuter des résultats. Les investisseurs peuvent accéder à la diffusion en direct via le lien fourni, et les participants par téléphone sont invités à s'inscrire et à se connecter 10 minutes avant le début de l'événement.
Neuronetics (NASDAQ: STIM), ein Medizintechnologieunternehmen, das sich auf Behandlungslösungen für neurogesundheitliche Störungen spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für Dienstag, den 5. August 2025, vor Börsenbeginn, geplant.
Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können über den bereitgestellten Link an der Live-Webcast teilnehmen, und Telefonteilnehmer werden gebeten, sich 10 Minuten vor Beginn der Veranstaltung zu registrieren und beizutreten.
- None.
- None.
MALVERN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2025 financial and operating results prior to market open on Tuesday, August 5, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/d6qidqaw. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 7.1 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
When will Neuronetics (STIM) release Q2 2025 earnings?
What time is Neuronetics' Q2 2025 earnings call?
How can I listen to Neuronetics' Q2 2025 earnings call?
What does Neuronetics (STIM) company do?
